Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Effects of nateglinide and rosiglitazone on pancreatic alpha- and beta-cells, GLP-1 secretion and inflammatory markers in patients with type 2 diabetes: randomized crossover clinical study

Fig. 2

Test with a standardized 500 calories mixed breakfast for 5 h: blood glucagon like peptide-1(GLP-1), free fat acids (FFA) and triglyceride levels. N1 and N2 before and after 4 months of nateglinide therapy. R1 and R2 before and after 4 months of rosiglitazone therapy. Hatched area: data of normal controls. Data were analyzed by the area under the curve using the trapezoidal rule and by Wilcoxon test for every time for the 5 h duration (p < 0.05)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us